Instructions TF101K
Instructions TF101KS

Description

Transfection, the introduction of nucleic acid into cells, is a powerful technique used to study in vivo gene function and regulation. The Cytofect™ Endothelial Cell Transfection kit is a plasmid DNA delivery system specifically optimized to deliver DNA into a wide variety of endothelial cells. This kit contains Cytofect-2, Enhancer, and Media for transfection and culturing cells.  Peptide Enhancer complexes with DNA and Cytofect-2 and escorts the transfection complex to the nucleus.  This results in high transfection efficiency and viability for these traditionally hard-to-transfect primary endothelial cells.
#Wells / Rxns
96 / 1000
24 / 250
12 / 125
The Kit contains all necessary reagents, media and optimized protocols to carry out successful transfection of endothelial cells with high efficiency (40%-85%) and viability (80%-95%).
Products are for research use only. They are not intended for human, animal, or diagnostic applications. TR1 and PE are manufactured by Targeting Systems.
 
(Click to Enlarge) Transfection of HUVEC (Top) and HCAEC (Bottom) with a GFP-expression plasmid using the Cytofect-HUVEC and Endothelial Cell Transfection Kits, respectively.

Details

Kit Contents:
 
 
 
Cytofect-2
Peptide Enhancer (PE)
Antibiotics-Free Growth Medium
Transfection Medium
Related products:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HAOEC
HCAEC
HDLMVEC
HDMVEC
HPAEC
HLMVEC
HPAEC
HUVEC
BAOEC
BCAEC
BPAEC
PPAEC
RAOEC
RBMVEC
Human Endothelial Cells
Animal Endothelial Cells
Cytofect HUVEC Transfection Kit
Cytofect Epithelial Cell Transfection Kit
Cytofect Fibroblast Transfection Kit
Cytofect Cell Line Transfection Kit
 
Designed to improve transfection efficiency and cell viability, Cytofect is a plasmid DNA delivery system containing Cytofect-2, Enhancer and Media for transfecting and culturing cells. The Enhancer is an endosomolytic peptide that complexes with DNA and Cytofect-2, then escorts the transfection complex to the nucleus. The results are high transfection efficiency and viability for traditionally hard-to-transfect cells.
Instructions TF101K

Format: PDF

Download Now
Instructions TF101KS

Format: PDF

Download Now

Products

Product Size CAT.# Price Quantity
Cytofect™ Endothelial Cell Transfection Kit: 250 x 24-Well Rxns Size: 1 Kit CAT.#: TF101K Price: $431.00
-+
Cytofect™ Endothelial Cell Transfection Kit: 25 x 24-Well Rxns Size: 1 Sample Kit CAT.#: TF101KS Price: $54.00
-+

Related Products

Product Size CAT.# Price Quantity
Cytofect-1 (CF1): Store at -20°C Size: 250 ul CAT.#: 051-250 Price: $152.00
-+
Cytofect-1 (CF1): Store at -20°C Size: 500 ul CAT.#: 051-500 Price: $246.00
-+
Cytofect-2 (CF2) : Store at 4°C Size: 250 ul CAT.#: 052-250 Price: $152.00
-+
Cytofect-2 (CF2) : Store at 4°C Size: 500 ul CAT.#: 052-500 Price: $246.00
-+
Peptide Enhancer (PE): Store at 4°C Size: 500 ul CAT.#: 053-500 Price: $205.00
-+
Peptide Enhancer (PE): Store at 4°C Size: 250 ul CAT.#: 053-250 Price: $123.00
-+
Viral Enhancer (VE): Store at -20°C Size: 250 ul CAT.#: 054-250 Price: $123.00
-+
Viral Enhancer (VE): Store at -20°C Size: 500 ul CAT.#: 054-500 Price: $205.00
-+

Resources/Documents

Publications

2016
Sahoo, S., D. Meijles, I. Ghouleh, M. Tandon, E. Cifuentes-Pagano, J. Sembrat, M. Rojas, E. Goncharova and P. Pagano. 2016. MEF2C-MYOCD and Leiomodin1 Suppression by miRNA-214 Promotes Smooth Muscle Cell Phenotype Switching in Pulmonary Arterial Hypertension. PLoS ONE, dx.doi.org/10.1371/journal.pone.0153780.
2015
Dokun, A., L. Chen, M. Okutsu, C. Farber, S. Hazarika, W. Jones, D. Craig, D. Marchuk, J. Lye, S. Shan, and B. Annex. 2015. ADAM12: A Genetic Modifier of Pre-clinical Peripheral Arterial Disease. Am J Physiol, DOI: 10.1152/ajpheart.00803.2014.
Zelko, I., and R. Folz. 2015. Regulation of Oxidative Stress in Pulmonary Artery Endothelium: Modulation of EC-SOD and NOX4 Expression Using HDAC Class I Inhibitors. Am J Respir Cell Mol Biol, DOI: 10.1165/rcmb.2014-0260OC.
2013
Chen, Z., T.C. Lai, Y.H. Jan, F.M. Lin, W.C. Wang, H. Xiao, Y.T. Wang, W. Sun, X. Cui, Y.S. Li, T. Fang, H. Zhao, C. Padmanabhan, R. Sun, D.L. Wang, H. Jin, G.Y. Chau, H.D. Huang, M. Hsiao, and J.Y.J. Shyy. 2013. Hypoxia-responsive miRNAs target argonaute 1 to promote angiogenesis. The Journal of Clinical Investigation. 123:1057-1067.
He, M., X. Liang, L. He, W. Wen, S. Zhao, L. Wen, Y. Liu, J.Y.J. Shyy, and Z. Yuan. 2013. Endothelial dysfunction in rheumatoid arthritis: the role of monocyte chemotactic protein-1-induced protein. Arteriosclerosis, Thrombosis, and Vascular Biology. 33:1384-1391.
Yan, Y., X. Li, K. Kover, M. Clements, and P. Ye. 2013. CREB participates in the IGFIstimulation cyclin D1 transcription. Developmental Neurobiology. 73:559-570.
2012
Jeon, Y.J., M.G. Jo, H.M. Yoo, S.H. Hong, J.M. Park, S.H. Ka, K.H. Oh, J.H. Seol, Y.K. Jung, and C.H. Chung. 2012. Chemosensitivity is controlled by p63 modification with ubiquitin-like protein ISG15. The Journal of Clinical Investigation. 122:2622-2636.